Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks

Journal of Hypertension

Volumn 24, Issue 11, 2006, Pages 2157-2159

  Campese, Vito M ^a   Park, Jeanie ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; EPLERENONE; PLACEBO; SPIRONOLACTONE;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; ALDOSTERONE RELEASE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG DOSE REDUCTION; EDITORIAL; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 33750264932     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000249690.88865.90     Document Type: Editorial

References (37)

1. Ibrahim HN, Rosenberg ME, Hostetter TH. Role of the renin - angiotensin - aldosterone system in the progression of renal disease: A critical review. Semin Nephrol 1997; 17:431-440.
2. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1003-2000.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
4. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57:601-606.
5. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
7. Sato A, Hayashi K, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41:64-68.
8. Greene E, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98:1063-1068.
9. Epstein M. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis 2001; 37:677-688.
10. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66:1-9.
11. McElvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999; 10:1056-1064.
12. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31:451-458.
13. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41:326-333.
14. Rocha R, Chander PN, Zuckerman A, Stier CT. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33:232-237.
15. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Remission of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16:3306-3314.
16. Hene RJ, Boer P, Koomans HA, Dorhout Mees EJ. Plasma aldosterone concentration in chronic renal failure. Kidney Int 1982; 21:98-101.
17. Berl T, Katz FH, Henrich WL, de Torrente A, Schrier R. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978; 14:228-235.
18. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M. The effects of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21:471-475.
19. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease [letter to the editor]. N Engl J Med 2001; 345:925-926.
20. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46:45-51.
21. Epstein M, Weinberger M, Lewin A, Martinez F, He W, Krause S. The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia. J Am Soc Nephrol 2003; 14:6A.
22. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effects of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitory therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1:256-262.
23. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68:2829-2836.
24. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care 2005; 28:2106-2112.
25. Van den Meiracker AH, Baggen RGA, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F. Spironalactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24:2285-2292.
26. Schmidt BMW, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE. Rapid non genomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47:650-655.
27. Chun TY, Pratt JH. Non genomic renal effects of aldosterone. Dependency on NO and genomic actions. Hypertension 2006; 47:636-637.
28. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, et al. Non genomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14:2255-2263.
29. Arima S, Kohagura K, Xu HL, Sugawara A, Uruno A, Satoh F, et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004; 43:352-357.
30. De Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43:41-47.
31. Watisaka M, Spiro MJ, Spiro RG. Synthesis of type IV collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes 1995; 43:95-103.
32. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-I. Hypertension 1998; 32:966-971.
33. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283:F209-F220.
34. Sun Y, Zhang J, Zhang JQ, Ramires FJA. Local angiotensin II and transforming growth factor-β in renal fibrosis in rats. Hypertension 2000; 35:1078-1084.
35. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63:43-52.
36. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, et al. Eplerenone shows renoprotective effect by reducing LOX-1 mediated adhesion molecule, PKCe-MAPK-p90RSK, and Rho-Kinase Pathway. Hypertension 2005; 45:538-544.
37. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47:1084-1093.